Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stavudine ER vs IR Long-Term Safety in HIV
NCT00116298Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2001
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label trial of stavudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Frequency and severity of Adverse Events and treatment discontinuations, Proportion of subjects with HIV RNA <400 copies/mL and 2 more. Started Jan 2001; status: completed.
02
Drugs
stavudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00116298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116298.